首页> 外文期刊>Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners >Cytotoxics compounded sterile preparation control by HPLC during a 16-month assessment in a French university hospital: importance of the mixing bags step.
【24h】

Cytotoxics compounded sterile preparation control by HPLC during a 16-month assessment in a French university hospital: importance of the mixing bags step.

机译:在法国大学医院进行的为期16个月的评估中,通过HPLC进行了细胞毒性复合无菌制剂控制:混合袋步骤的重要性。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The Centralized Chemotherapy Reconstitution Unit (CCRU) of Paul Brousse Hospital Pharmacy Department assessed the reliability of its Cytotoxics Compounded Sterile Products (CCSP) preparation method in order to improve its CCSP quality assurance system. Five cytotoxic drugs - gemcitabine, 5-fluorouracil, docetaxel, paclitaxel, and oxaliplatin - were assayed by high performance liquid chromatography (HPLC) to determine CCSP concentration. During the observation period, 23,892 CCSP were prepared. Overall, 12,964 preparations contained one of the five analyzed drugs; 7382 (56.9%) out of 12,964 CCSP were analyzed by HPLC; 646 (8.8%) out of 7382 concentrations were outside +/- 20% of the prescribed dose; 544 (84.2%) out of 646 were post-administration results and could not be verified. Out of 102 (15.8%) pre-administration results that were re-tested after re-shaking, 94 (92.2%) were found to be acceptable upon re-testing, and 8 (7.8%) were confirmed to be unacceptable and needed to be re-compounded. The 8.8% of tested CCSP were outside +/- 20% of the prescribed dose, but extrapolating the results on re-tested CCSP, we can say that our CCSP preparation is reliable with an estimation of only 0.7% of 7382 CCSP analyzed, confirmed as being +/- 20% outside the prescribed dose. Nevertheless, this +/- 20% magnitude of error should be reduced. Based on pre-administration results, the primary cause of concentration errors appeared to be insufficient mixing of the finished product. Most CCSP dosages occurred after it had been administered, the organization should, therefore, be improved to include testing all CCSP prior to administration. Pharmaceutical companies should endeavor to manufacture compounded injectible drugs in a 'ready to use' form and provide vehicles in accurate volumes in order to improve compounding precision.
机译:Paul Brousse医院药房的中央化学治疗重建部门(CCRU)评估了其细胞毒素复合无菌产品(CCSP)制备方法的可靠性,以改善其CCSP质量保证体系。通过高效液相色谱(HPLC)测定了五种细胞毒性药物-吉西他滨,5-氟尿嘧啶,多西他赛,紫杉醇和奥沙利铂-测定CCSP浓度。在观察期内,准备了23892份CCSP。总体而言,有12964种制剂包含了五种被分析药物之一。 HPLC分析了12,964个CCSP中的7382(56.9%);在7382种浓度中,有646种(8.8%)超出规定剂量的+/- 20%; 646人中有544人(84.2%)是给药后的结果,无法验证。在重新摇动后重新测试的102份(15.8%)预给药结果中,经重新测试发现94份(92.2%)可以接受,并且已确认8份(7.8%)是不可接受的并且需要重新复合。经测试的CCSP的8.8%超出了规定剂量的+/- 20%,但根据重新测试的CCSP的结果推断,我们可以说我们的CCSP制备是可靠的,估计分析的7382 CCSP仅占0.7%,超出规定剂量+/- 20%。但是,应减小+/- 20%的误差幅度。根据给药前的结果,浓度误差的主要原因似乎是成品混合不充分。大多数CCSP剂量是在给药后发生的,因此,应改善组织以包括在给药前测试所有CCSP。制药公司应努力以“即用型”形式生产复合注射剂,并提供准确数量的载剂,以提高复合精度。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号